Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Bullish +75

Aflac Earnings Call Highlights Japan Surge and Strength

AI-generated analysis

πŸ“ˆ Aflac reported Q1 adjusted earnings per diluted share of $1.75, representing a 6.6% year-over-year increase.

πŸ‡―πŸ‡΅ Japan sales surged 25.5% in the first quarter driven by new products like Onsen Tallett and the Miraito cancer line.

πŸ‡ΊπŸ‡Έ U.S. sales grew 2.9% with net earned premium increasing 3.5%, supported by a premium persistency rate of 79.3%.

πŸ’° The company returned approximately $1.3 billion to shareholders through share repurchases and dividends in the quarter.

πŸ“Š Japan's pretax margin climbed to 35%, up 320 basis points, while the U.S. business maintained a 20.4% pretax margin.

⚠️ Japan's net earned premiums fell 3.8% in yen terms due to lapses and paid-up policy migrations offsetting new sales.

🏦 Aflac holds $3.4 billion of unencumbered liquidity, which is roughly $2.4 billion above its internal minimum threshold.

πŸ”„ The company assumed a reinsurance block from Japan Post Insurance to position reinsurance as a future growth engine.

βš–οΈ Total benefit ratios improved across segments, with Japan at 62.9% and the U.S. at 47.2%, aided by reserve remeasurement gains.

πŸ“‰ The Corporate & Other segment slipped to breakeven pretax adjusted earnings due to lower investment income and higher interest expenses.

🏒 Aflac recorded $19 million in loan charge-offs and $24 million in impairments on real estate owned reflecting commercial real estate weakness.

πŸ“ˆ U.S. group products grew 12.4% for the quarter with a targeted mix of life, absence, disability, and consumer markets up roughly 25%.

🎯 Management reaffirmed full-year guidance for Japan's benefit ratio between 60% and 63% and the U.S. between 42% and 52%.

πŸ“‰ An external reinsurance transaction modestly reduced Japan earnings by a mid-single-digit U.S. dollar amount in the quarter.

πŸ“‰ The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions.

Bullish Signals
  • Aflac Japan delivered a 25.5% jump in first-quarter sales, driven by new products like the Onsen Tallett medical product and the Miraito cancer line.
  • Adjusted earnings per diluted share rose to $1.75, representing about 6.6% growth year over year, with favorable reserve remeasurement gains of $82 million adding roughly $0.04 per share.
  • In the U.S., sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention as premium persistency reached 79.3%.
  • Company-wide profitability remained compelling with adjusted return on equity at 12.8%, and Japan's pretax margin climbed to 35%, up 320 basis points.
  • Aflac underscored a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum.
  • The company returned about $1.3 billion to shareholders in the quarter through roughly $1.0 billion of share repurchases and $315 million of dividends, extending its multi-decade dividend growth streak.
  • Japan's total benefit ratio improved to 62.9%, a 290-basis-point year-over-year decline, aided by favorable claims experience.
  • The U.S. group segment continued to gain traction with group products up about 12.4% for the quarter and targeted mix growth of roughly 25%.
  • Management reaffirmed full-year guidance for Japan's benefit ratio at 60%-63% and the U.S. at 42%-52%, signaling confidence in maintaining disciplined underwriting.
  • Aflac plans to keep adjusted leverage within its 20%-25% corridor and continue tactical capital deployment to support shareholder returns.
Risk Factors
  • Japan's net earned premiums fell 3.8% in yen terms, with underlying earned premiums down 1.3%, reflecting lapses and paid-up policy migrations that new sales have not yet fully offset.
  • Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned, reflecting continued weakness in commercial real estate markets.
  • U.S. statutory impairments totaled $12 million, alongside a small mortgage loan valuation allowance and variable investment income running about $14 million below long-term expectations.
  • The U.S. expense ratio rose to 38.3%, up 70 basis points year over year, driven by higher DAC amortization and commissions.
  • An external reinsurance transaction ceding first-sector business modestly reduced Aflac Japan earnings by a mid-single-digit U.S. dollar amount in the quarter, with expectations of slightly negative impact for the next few quarters.
  • Achieving flat earned premium in Japan would require about JPY 90 billion of annual sales, compared with roughly JPY 74 billion generated in 2025, signaling a need for further execution gains to offset policy lapses.
Full Analysis
Aflac Incorporated reported first-quarter earnings driven by strong new-business momentum in Japan, where sales surged 25.5% fueled by new products like the Onsen Tallett medical line and the Miraito cancer line. Adjusted earnings per diluted share rose to $1.75, or approximately $1.77 excluding foreign-exchange effects, representing about 6.6% year-over-year growth. This performance was aided by favorable reserve remeasurement gains of $82 million, which added roughly $0.04 per share and helped lift results above internal plans. In the United States, sales increased 2.9% while net earned premium grew 3.5%, supported by strong retention with premium persistency reaching 79.3%. Group voluntary products showed particular strength, helping stabilize and expand the U.S. franchise, with group segment growth of about 12.4% for the quarter. Company-wide profitability remained compelling, with adjusted return on equity at 12.8%, while Japan’s pretax margin climbed to 35% and the U.S. business held a solid pretax margin of 20.4%. The company maintained a strong balance sheet with $3.4 billion of unencumbered liquidity, roughly $2.4 billion above its internal minimum, and adjusted leverage of 21.2% within its target range. Aflac returned about $1.3 billion to shareholders through share repurchases and dividends, extending its multi-decade dividend growth streak. Strategic progress was noted at Aflac Re Bermuda, which assumed a block from Japan Post Insurance, positioning reinsurance as a future growth engine. However, challenges included softer earned premiums in Japan, investment and reserve volatility, and a weaker Corporate & Other segment that slipped to roughly breakeven pretax adjusted earnings due to lower investment income and higher interest expenses. Credit and real estate investments faced pressure with $19 million of loan charge-offs and $24 million of impairments on real estate owned. Management reaffirmed full-year guidance for Japan’s benefit ratio at 60%–63% and the U.S. at 42%–52%, signaling confidence in maintaining disciplined underwriting despite near-term headwinds from investment volatility and higher expenses.